Phenotypic Detection of Extended Spectrum β-Lactamase and AmpC producing Enterobacteriaceae Isolated in A General Hospital

Yıl 2018, Cilt: 08 Sayı: 03, 113 - 119, 15.09.2018

Cecile Okalla Ebongue Roane Nkodo Mengue Jean-pierre Nda Mefo’o Elvis Temfack Emmanuel Roddy Mengue Dieudonne Adiogo

https://doi.org/10.5799/jmid.458461

Cited By: 2

Öz

Objective: The antibiotic resistance of Enterobacteriaceae is a worldwide preoccupation, and misuse
antibiotics of beta-lactam group allowed the development of bacteria producing
extended spectrum beta-lactamase and cephalosporinase AmpC enzymes type
resistance. The aim of this study was to determine the frequency of these
enzymes among strains isolated at the General Hospital in Douala, Cameroon.

Methods: We
conducted a cross-sectional study. For phenotypic detection of resistance
enzymes, MASTDISCS™ test impregnated third and fourth generation
cephalosporin’s was used by diffusion on Mueller Hinton agar. Measuring the
inhibition areas and comparing the inhibition diameters determined the nature
of the resistance mechanism.

Results: This
study included 195 strains of Enterobacteriaceae.
The most frequent species were Escherichia
coli and Klebsiella pneumoniae,
with a frequency of 49.2% and 31.3% respectively. After determination of
resistance phenotypes, 101 (51.8%) isolates were found to be producing
resistance enzymes. The frequency of ESBL-producing Enterobacteriaceae was 19.5%; AmpC producing was 14.3% and both
enzymes (AmpC + ESBL) 17.9%. E. coli
and K. pneumoniae resistance rates
were 90% and 83.7% for Cotrimoxazole, 82.5% and 78.3% for ciprofloxacin, 20%
and 13.5% for Amikacin, respectively. Imipenem, Amikacin and Fosfomycin were
the most active molecules with 4.9%, 19.8% and 33.6%, out of 101 resistant
strains, respectively.

Conclusion: This study showed a high frequency of resistance
enzyme producing strains. This situation leads to resistance to antibiotics
most commonly used. This finding justifies a change in prescription habits for
protection of molecules that are still active. J Microbiol Infect Dis 2018; 8(3):113-119

Anahtar Kelimeler

AmpC, Cameroon, Enterobacteriaceae, ESBL, Resistance

Kaynakça

• 1. Kumamoto Y, Tsukamoto T, Matsukawa M, et al. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution. Jpn J Antibiot 2006; 59:177-200. 2. Walsh C. Antibiotics: actions, origins, resistance. American Society for Microbiology (ASM), 2003. 3. World Health Organization. The World Health Report 2000: Health Systems: improving performance. World Health Organization, 2000. 4. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001; 32:675-685. 5. Dosso M, Bissagnene E, Coulibaly M, et al. Résistances acquises et prescriptions d'antibiotiques en Afrique: quelles adéquations? Med Mal Inf 2000; 30:s197-s204. 6. Livermore DM. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8:557-584. 7. Livermore DM. β-lactamase mediated resistance: past, present and future. J Infect Dis Sci 1995; 6:75-83. 8. Bush K, Mobashery S. How β-lactamases have driven pharmaceutical drug discovery. In Resolving the Antibiotic Paradox. Springer US, 1998: 71-98 9. Matagne A, Lamotte-Brasseur J, Frère JM. Catalytic properties of class a β-lactamases: efficiency and diversity. Biochem J 1998; 330:581-598. 10. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39:1211. 11. Gupta V, Datta P. Extended-spectrum beta-lactamases (ESBL) in community isolates from North India: frequency and predisposing factors. Int J Infect Dis 2007; 11:88-89. 12. Gangoué-Piéboji J, Bedenic B, Koulla-Shiro S, et al. Extended-spectrum-β-lactamase-producing Enterobacteriaceae in Yaounde, Cameroon. J Clin Microbiol 2005; 43:3273-3277. 13. Lonchel CM, Meex C, Gangoué-Piéboji J, et al. Proportion of extended-spectrum ß-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon. BMC Infect Dis 2012; 12:53. 14. Ebongue CO, Tsiazok MD, Mefo'o JP, Ngaba GP, Beyiha G, Adiogo D. Evolution of antibiotic resistance of Enterobacteriaceae isolated at the Douala General Hospital from 2005 to 2012. Pan Afr Med J 2015; 20:227-227. 15. Raji MA, Jamal W, Ojemhen O, Rotimi VO. Point-surveillance of antibiotic resistance in Enterobacteriaceae isolates from patients in a Lagos Teaching Hospital, Nigeria. J Infect Public Health 2013; 6:431-437. 16. Singhal S, Mathur T, Khan S, et al. Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol 2005; 23:120. 17. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32:S94-S103. 18. Lemaître N, Loïez C, Pastourel N, et al. Detection of extended-spectrum ß-lactamase-producing Enterobacteriaceae in rectal swabs with the Mastdiscs™ ID AmpC ßLSE detection set. Pathol Biol 2012; 60:e41-e44. 19. Black JA, Moland ES, Thomson KS. AmpC disk test for detection of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking chromosomal AmpC β-lactamases. J Clin Microbiol 2005; 43:3110-3113. 20. Nasim K, Elsayed S, Pitout JDD, Conly J, Church DL, Gregson DB. New method for laboratory detection of AmpC β-lactamases in Escherichia coli and Klebsiella pneumoniae. J Clin Microbiol, 2004; 42:4799-4802. 21. Thomson KS. Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 2010; 48:1019-1025. 22. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS. Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 US hospitals. Antimicrob Agents Chemother 2002; 46:3837-3842. 23. Manoharan A, Sugumar M, Kumar A, Jose H, Mathai D, ICMR-ESBL Study Group. Phenotypic & molecular characterization of AmpC β-lactamases among Escherichia coli, Klebsiella spp. & Enterobacter spp. from five Indian Medical Centers. Indian J Med Res 2012; 135:359. 24. Jarlier V. Phenotypes de resistance aux β-lactamines: Description et fréquence, place d'E. cloacae. Med Mal Inf 1998; 18:32-40. 25. Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC β-lactamase-producing organisms. Ann Pharmacother 2007; 41:1427-1435. 26. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53:2227-2238. 27. Mehrgan H, Rahbar M, Arab-Halvaii Z. High prevalence of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Tehran, Iran. J Infect Dev Ctries 2009; 4:132-138. 28. Barguigua A, El Otmani F, Talmi M, et al. Characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from the community in Morocco. J Med Microbiol 2011; 60:1344-1352. 29. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002; 46:1-11.